ClinicalTrials.gg
Not yet recruitingNCT07238244Updated Nov 20, 2025

Risk Factors for Recurrence of Trigeminal Neuralgia After Percutaneous Balloon Compression

An observational study in Trigeminal Neuralgia, sponsored by Second Xiangya Hospital of Central South University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Second Xiangya Hospital of Central South University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to develop and validate a machine learning-based model for predicting pain recurrence risk after percutaneous balloon compression (PBC) in adult patients with primary trigeminal neuralgia (TN) who had their first PBC treatment. The main questions it aims to answer are:

Can the machine learning-based model accurately predict pain recurrence after PBC in these primary TN patients? What key factors (like patient baseline traits, imaging parameters, surgical operation data) affect PBC post-operative pain recurrence? Do machine learning algorithms perform better than traditional Cox proportional hazards regression in predicting such recurrence? Participants (with existing PBC treatment records) will have their past data-including clinical info from the hospital's electronic medical record system, imaging data from the image archiving system, surgical data from the surgical anesthesia system, and follow-up data from the outpatient system-collected and analyzed to build and validate the prediction model.

02

Conditions studied

  • Trigeminal Neuralgia

Browse trials for

Keywords

  • Trigeminal Neuralgia
  • Percutaneous Balloon Compression
  • predication
  • Machine Learning Model
03

In context

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

This study's planned enrollment of 700 is above the median of 84 across 38 observational studies indexed under Trigeminal Neuralgia.

Browse Trigeminal Neuralgia studies →

Lead sponsor

Second Xiangya Hospital of Central South University is the lead sponsor of 87 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (aged ≥ 18 years) who underwent percutaneous balloon compression (PBC) with primary trigeminal neuralgia (TN) who had their first PBC treatment at the Department of Pain Medicine, the Second Xiangya Hospital of Central South University between January 2018 and June 2025, and were willing to participate in postoperative follow-up were selected as the study subjects

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years.
  2. Meet the diagnostic criteria for primary trigeminal neuralgia according to the International Classification of Headache Disorders, 3rd edition (ICHD-3).
  3. Undergo the first PBC treatment.
  4. Have complete preoperative clinical data, imaging data, and intraoperative records.
  5. Have at least one postoperative follow-up record available for determining the recurrence status.

Exclusion criteria

Exclusion Criteria:

  1. Secondary trigeminal neuralgia (e.g., caused by cerebellopontine angle tumors, multiple sclerosis, etc.).
  2. Missing rate of key predictor variables (e.g., balloon shape) or outcome variables > 15%.
  3. Postoperative loss to follow-up (defined as no follow-up records available).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
700 participants (estimated)
Patient registry
No

Interventions

  • ProcedurePercutaneous Balloon Compression

    The intervention studied is Percutaneous Balloon Compression (PBC). It is a minimally invasive surgical intervention used for the treatment of primary trigeminal neuralgia (TN), which involves percutaneously inserting a balloon to compress the trigeminal ganglion, aiming to relieve pain in patients with TN who are unresponsive to drug therapy or unable to tolerate drug adverse reactions.

06

What researchers measure

Primary outcomes

  1. Pain Recurrence After Percutaneous Balloon Compression in Patients with Primary Trigeminal Neuralgia

    The primary outcome measure focuses on whether pain recurrence occurs in patients with primary TN after their first PBC treatment, defined as a dichotomous variable ("recurred" or "not recurred"). Recurrence Criteria: Postoperative pain intensity, as assessed by the Barrow Neurological Institute Pain Intensity Score, rebounds to Grade IV ("persistent pain controllable with medication") or Grade V ("severe pain uncontrollable with medication"), and this pain status persists for at least 1 week. Additionally, the recurrence must be accompanied by the need to increase the dose of pain medication or undergo reinterventional treatment (e.g., repeated PBC or other surgical procedures) to manage the pain.

    Time frame: through study completion, an average of 3 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The Individual Participant Data (IPD) to be shared in this study will be strictly de-identified (with all personal identifiers such as names, ID numbers, hospital admission numbers, and contact information removed and replaced with unique study serial numbers) and limited to data relevant to verifying the research objectives.Raw imaging files, full electronic medical records, and any sensitive data unrelated to the study's prediction model verification will not be included in the shared IPD to ensure participant privacy and data security.

Supporting information: Study protocol, Statistical analysis plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Feb 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Nov 20, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Feb 15, 2026
CompletionEst.
Mar 15, 2026
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07238244
Lead sponsor
Second Xiangya Hospital of Central South University
Collaborators
Yueyang Hospital of Traditional Chinese Medicine
Responsible party
YaPing Wang (Professor, Second Xiangya Hospital of Central South University) — Principal investigator
First posted
Nov 20, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Feb 15, 2026 (estimated)
Completion
Mar 15, 2026 (estimated)
Last update
Nov 20, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion